3D Systems enters Thursday's earnings call with nearly a third of its float sold short and the stock up 62% in a month — a combustible combination that turned explosive this week.
The stock closed at $3.11 on Tuesday, a 24% single-day gain and 20% on the week. The one-month move of 62% — from a low of $1.92 — has been driven in part by short-covering pressure rather than any fundamental re-rating. The ORTEX short score of 80.5 ranks in the bottom percentile of the universe, marking this as one of the most heavily shorted names in the market right now.
The positioning story is striking. Short interest is 29% of the free float and climbed 6.3% week-on-week — shorts were actually adding exposure as the stock rallied. That is a notable divergence: the price moved aggressively higher while the short count grew. The FINRA fortnightly report put covered short shares at 41.3 million with 14.6 days to cover, underlining how long it would take to unwind that position in normal volume. Cost to borrow remains unremarkable at 0.58%, barely changed on the month — there is no borrow-market signal of panic among shorts. Availability has eased somewhat, with the lending pool now at roughly 48% of outstanding short interest, down from tighter levels seen in April but well below the 100% 52-week extreme hit earlier in the year. That still constitutes a relatively tight borrow environment. Options traders are leaning the other way: the put/call ratio at 0.124 is near its 52-week low and running just below its 20-day average, suggesting call buyers are driving options flow. The z-score of -1.05 confirms the lean toward bullish options positioning.
The Street is cautious but not bearish. Cantor Fitzgerald's Troy Jensen reiterated an Overweight with a $5 target on May 13 — the only analyst action in the past 30 days and directly relevant given the $3.11 close. That $5 target implies 61% upside and is the sole bullish voice in a thin coverage group. Needham has held a no-target Hold for over a year. The bull case centres on growth in personalized healthcare — up 17% year-on-year — and FDA-approved parts manufacturing up 18%, alongside $5m in operating cost savings. Bears point to the harder facts: Q1 revenue fell 8% year-on-year to $94.5m, missing estimates, with materials sales down 23% due to dental aligner inventory headwinds. The price-to-book sits at 0.53 — the market is pricing DDD below book value, reflecting ongoing earnings losses and a negative EV/EBITDA of -34.8x.
On the ownership side, insiders sold in two coordinated clusters in April. On April 1 and April 14, the CEO Jeffrey Graves sold a combined 70,451 shares at prices between $1.87 and $1.98. The company's founder and CTO Chuck Hull also sold in both windows. These were small in absolute dollar value — roughly $135,000 combined for Graves — and all carried a significance score of 1 out of 10, suggesting routine disposals rather than a directional signal. State Street added 1.56 million shares in the quarter to April 30, becoming the largest institutional holder at 7.8% of shares. TIAA nearly doubled its position, adding 2.17 million shares, while Morgan Stanley trimmed 1.39 million.
The closest US peer, SSYS, fell 4.1% on the week — giving back gains while DDD surged ahead, widening the performance gap between the two main publicly listed additive manufacturing names. MVST cratered 30% on the day and 28% on the week, a reminder of how violent moves can be across this cluster of small, heavily shorted stocks.
Tomorrow's earnings call is the immediate event to watch. The stock has already priced in a significant amount of short-squeeze momentum and options traders are positioned for further upside. Whether the Q1 print confirms the healthcare growth narrative or reaffirms the revenue decline story is the question the short position — still at 29% of the float — has yet to fully answer.
See the live data behind this article on ORTEX.
Open DDD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
